Linked Life Data

20509714

Source:http://linkedlifedata.com/resource/pubmed/id/20509714

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-5-31
pubmed:abstractText
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1179-6901
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:pagination
37-45
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
pubmed:publicationType
Journal Article, Review